Amoxicillin exhibited ZI between 21mm (Elys) and 23mm (Zenufa) against E. coli, and between 21mm and 23mm (Elys) against S. aureus. Ampicillin samples yielded ZI from 20mm (India) to 25mm (Keko) against both bacteria. Dicloxacillin exhibited ZI between 13mm (Keko) and 16mm (India, Keko) against E. coli and from 15mm (Keko) to 18mm (Shelys) against S.aureus. Ciprofloxacin samples (India) exhibited ZI between 22mm and 25mm against both bacteria. On the other hand ketoconazole exhibited ZI between 16.5 and 19.0 mm against both Candida albicans and Cryptoccocus neoformans. Nystatin (Cyprus) produced ZI between 10 and 12mm against both fungi; similarly Fluconazole (India) yielded between 16.5 and 20mm of ZI against both C. albicans and C. neoformans. The antimicrobial agents analyzed in this study have demonstrated substantial antimicrobial activities against the test microorganisms, an indicative of possession of active ingredients. As far as the in vitro microbiological assays are concerned, the study’s findings could not reveal any counterfeit drug. However, further studies should be conducted to confirm the content specifications and other relevant parameters of each pharmaceutical preparation.